Oncology News Today

23/03/2026

📰 NEWS: NICE publishes its first kidney cancer guideline, set to double biopsy rates and prevent hundreds of unnecessary surgeries each year

The National Institute for Health and Care Excellence (NICE) has published its first comprehensive clinical guideline on kidney cancer.

This landmark guideline follows years of campaigning, evidence gathering, and expert input from Kidney Cancer UK – whose Accord panel and clinical advisors worked closely with NHS England and NICE to demonstrate the need for clearer diagnostic standards, greater use of biopsy, and more consistent national care pathways.

Read more: https://oncologynewstoday.co.uk/nice-publishes-its-first-kidney-cancer-guideline-set-to-double-biopsy-rates-and-prevent-hundreds-of-unnecessary-surgeries-each-year/

Pictured: Andrew Greaves, General Manager at Kidney Cancer UK

The National Institute for Health and Care Excellence has published its first comprehensive clinical guideline on kidney cancer.

20/03/2026

📰 NEWS: New study reveals key enzyme as hidden driver of cancer stress responses

Researchers have identified the enzyme DHX8 as a crucial regulator of the stress‑response protein HSF1. This discovery deepens the scientific understanding of how cancers develop and resist treatment, and it may have potential to open new avenues for future drug development.

Co‑senior author Dr Paul Clarke, Group Leader in RNA Biology and Molecular Therapeutics at the ICR, said: “Our research reveals an entirely new layer of control in the stress‑response machinery on which cancer cells depend. DHX8 is not just an accessory splicing factor – it appears to be indispensable for the proper processing of HSF1 and a range of other transcripts that help tumour cells survive stressful conditions.”

Read more: https://oncologynewstoday.co.uk/new-study-reveals-key-enzyme-as-hidden-driver-of-cancer-stress-responses/

The Institute of Cancer Research Cancer Research UK

An important study has uncovered an unexpected molecular player that helps make cancer cells stress-resilient, thereby promoting the survival, growth and progression of tumours.

19/03/2026

📰 NEWS: First Hampshire Hospitals NHS Foundation Trust patient receives treatment in groundbreaking prostate cancer trial

Hampshire Hospitals is one of only five hospitals in the UK to recruit participants into this major global study, marking a significant milestone in the Trust’s contribution to prostate cancer research.

Unlike traditional treatments, Aquablation uses a robotic assisted, high-pressure waterjet to precisely remove prostate tissue. It avoids thermal damage and is designed to preserve key structures around the prostate, helping reduce the risk of life altering side effects commonly associated with treatments such as radical prostatectomy (complete prostate removal).

Read more: https://oncologynewstoday.co.uk/first-hampshire-hospitals-patient-receives-treatment-in-groundbreaking-prostate-cancer-trial/

Pictured: Hampshire Hospitals staff, including Consultant Urologist Dr Richard Hindley, with research trial patient Wayne Prosper

Hampshire Hospitals NHS Foundation Trust has successfully treated its first patient as part of a groundbreaking research trial exploring Aquablation therapy for localised prostate cancer.

18/03/2026

📰 NEWS: Cancer Research UK and NovalGen dose the first patient in the phase 1 trial of T-cell engager NVG-222

Cancer Research UK’s Centre for Drug Development (CDD) and NovalGen yesterday announced that the first patient has been dosed in a Phase 1 clinical trial evaluating NVG‑222, NovalGen’s next-generation self‑regulating T‑cell engager for the treatment of ROR1‑positive blood cancers.

The trial is sponsored and delivered by Cancer Research UK’s Centre for Drug Development and is led by Chief Investigator Will Townsend at UCLH - University College London Hospitals NHS Foundation Trust, where the first patient received treatment. Cancer Research Horizons is managing the commercial partnership between NovalGen and Cancer Research UK.

The study is enrolling patients across the UK with ROR1‑positive blood cancers and uses an adaptive design to optimise dose, treatment and biomarker strategies. Dosing of the first patient marks an important step in translating AutoRegulated immune therapies from the laboratory into clinical testing.

Read more:

Cancer Research UK’s Centre for Drug Development (CDD) and NovalGen yesterday announced that the first patient has been dosed in a Phase 1 clinical trial evaluating NVG‑222, NovalGen’s next-generation self‑regulating T‑cell engager for the treatment of ROR1‑positive blood cancers.

17/03/2026

❗️ JOB ALERT: Health New Zealand - Te Whatu Ora is seeking Medical Oncologists from the UK & Ireland to deliver high-quality systemic cancer care within hospital-based teams across New Zealand.

With an emphasis on collaboration between primary, secondary, and tertiary care, Medical Oncologists work closely with Surgeons, Radiologists, Pathologists, and Nurses to achieve the best outcomes for patients.

APPLY NOW: https://oncologynewstoday.co.uk/jobs/medical-oncologists/

17/03/2026

📰 NEWS: A new cancer support centre to be built in grounds of Maidstone Hospital has been granted planning permission

The Maggie’s centre will provide free, tailored practical and emotional support for people at all stages of cancer, as well as their family and friends.

It is expected the centre, which will be built in the grounds of Maidstone Hospital, part of Maidstone and Tunbridge Wells NHS Trust, will be supporting people living with cancer by 2028.

Read more: https://oncologynewstoday.co.uk/a-new-cancer-support-centre-to-be-built-in-grounds-of-maidstone-hospital-has-been-granted-planning-permission/

16/03/2026

📰 NEWS: HCA Healthcare UK's The Wellington Hospital has become the first private hospital in Europe to provide Histotripsy treatment, a breakthrough treatment for liver cancer.

Read more:

HCA Healthcare UK’s The Wellington Hospital has become the first private hospital in Europe to provide Histotripsy treatment, a breakthrough treatment for liver cancer.

13/03/2026

❗️ JOB ALERT: Health New Zealand - Te Whatu Ora is seeking Radiation Oncologists from the UK and Ireland to join multidisciplinary cancer services across New Zealand.

Working as a Radiation Oncologist in New Zealand offers a unique work-life balance in a clean, green, and safe environment. The country's healthcare system, particularly in Oncology, is recognised for its high standards and patient-centred care.

Radiation Oncologists have access to modern equipment and advanced technologies such as IMRT (Intensity-Modulated Radiation Therapy) and SBRT (Stereotactic Body Radiation Therapy).

APPLY NOW: https://oncologynewstoday.co.uk/jobs/radiation-oncologists/

13/03/2026

📰 NEWS: Five global teams awarded £100 million to take on the toughest challenges at the frontiers of cancer science

Cancer Grand Challenges, a global initiative co-founded by Cancer Research UK and the National Cancer Institute in the US, has announced a major £100m commitment to propel cancer research into unchartered territory.

Five pioneering international teams will each receive up to £20m over approximately five years to tackle some of the most ambitious and unanswered questions in cancer.

Bringing together a global coalition of the world’s leading scientists, funders and philanthropists, Cancer Grand Challenges enables bold, long-term collaboration to pursue disruptive ideas that could open entirely new routes for cancer prevention, detection, and treatment. This latest investment matches the previous record £100m funding round and brings the total support for the initiative to £465m since 2016.

Read more:

12/03/2026

📰 NEWS: Scientists discover new avenue for treating an aggressive form of breast cancer

New research funded by Breast Cancer Now has revealed that a gene typically active only in reproductive cells may hold the key to new treatments for triple negative breast cancer.

Around 15 per cent of breast cancers are classed as triple negative. This form of breast cancer can be more aggressive and harder to treat than other forms of the disease. It is also more common in women with an inherited altered BRCA gene, women under 40 years of age, and black women.

Scientists from the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research, London and the Breast Cancer Now Research Unit at King's College London, have uncovered a new weakness in triple negative breast cancer linked to a gene called HORMAD1 and a way to target it.

Read more: https://oncologynewstoday.co.uk/scientists-discover-new-avenue-for-treating-an-aggressive-form-of-breast-cancer/

Pictured: Professor Andrew Tutt, Director of the Breast Cancer Now Toby Robins Research Centre and The Breast Cancer Now Research Unit

New research funded by Breast Cancer Now has revealed that a gene typically active only in reproductive cells may hold the key to new treatments for triple negative breast cancer.

11/03/2026

📰 NEWS: C-Further unveils first therapeutic programmes dedicated to paediatric oncology

C-Further, an international consortium committed to creating new therapeutics for childhood cancers, today unveils the first early-stage therapeutic programmes for its pipeline, dedicated to paediatric oncology indications.

Through its collaborative model, C-Further has partnered with investigators at UVA Comprehensive Cancer Center, Dana-Farber Cancer Institute and Mass General Brigham to advance CF-012 for the potential treatment of Ewing sarcoma. In parallel, the consortium has partnered with investigators at MiNK Therapeutics (Nasdaq:INKT) to advance CF-033, leveraging MiNK’s proprietary platform with translational support by investigators at the University of Southampton, for the potential treatment of multiple children’s cancers, including bone sarcoma, medulloblastoma and acute myeloid leukaemia.

Read more: https://oncologynewstoday.co.uk/c-further-unveils-first-therapeutic-programmes-dedicated-to-paediatric-oncology/

UVA Health Cancer Research UK Great Ormond Street Hospital and Charity

C-Further, an international consortium committed to creating new therapeutics for childhood cancers, has unveiled the first early-stage therapeutic programmes for its pipeline, dedicated to paediatric oncology indications.

10/03/2026

📰 NEWS: Pioneering study finds AI increases cancer detection by more than 10 per cent

The UK’s first comprehensive evaluation of the use of artificial intelligence (AI) in breast cancer screening found that it can increase breast cancer detection by 10.4 per cent and has the potential to reduce the workload of healthcare workers by more than 30 per cent compared to the current clinical process.

Published today in Nature Cancer, the evaluation was carried out by a team of scientists, clinicians and software developers from the University of Aberdeen, NHS Grampian, and Kheiron Medical Technologies, now part of DeepHealth Inc., and was funded through the NHS AI in Health and Care Award in partnership with the National Institute for Health and Care Research.

Read more: https://oncologynewstoday.co.uk/pioneering-study-finds-ai-increases-cancer-detection-by-more-than-10-per-cent/

Pictured: Dr Clarisse de Vries and Professor Gerald Lip

The UK’s first comprehensive evaluation of the use of Artificial Intelligence in breast cancer screening found that it can increase breast cancer detection by 10.4 per cent and has the potential to reduce the workload of healthcare workers by more than 30 per cent compared to the current clinical ...